Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To explore the efficiency and safety of CLAG regimen in R/R ALL

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital of Soochow University
• Collaborators: Suzhou Municipal Hospital; The First People's Hospital of Changzhou; Zhongda Hospital
• Treatments: Cladribine; Cytarabine; Fludarabine; Methotrexate

Criteria

Inclusion Criteria:

The patients meet the diagnostic criteria for Relapsed/Refractroy B-ALL. ECOG score is 0-3. Expecting life span is more than 6 weeks.

Exclusion Criteria:

Patients are combined with severe organ dysfunction or organ failure: Cardiac failure, Liver and kidney insufficiency.

Patients are combined with severe infection or other complications that can not tolerate chemotherapy.

Patients are considered as other tumor progression. Patients have used cladribine. Pregnant and lactating women will not be included.